Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201758 | 0.82 | PDE5A (0.51) | PDE5APDE6C | |
| SCHEMBL6203003 | 0.81 | PDE5A (0.54) | PDE5APDE6C | |
| SCHEMBL6199000 | 0.80 | PDE5A (0.54) | PDE5APDE6C | |
| SCHEMBL6201755 | 0.79 | PDE5A (0.51) | PDE5APDE6C | |
| Trifluoroacetic Acid SCHEMBL6199599 | 0.77 | PDE5A (0.70) | PDE5APDE6C | |
| SCHEMBL6200033 | 0.76 | PDE5A (0.66) | PDE5APDE6C | |
| SCHEMBL6200867 | 0.76 | PDE5A (0.55) | PDE5APDE6C | |
| SCHEMBL6203579 | 0.75 | PDE5A (0.73) | PDE5APDE6C | |
| SCHEMBL6204272 | 0.73 | PDE5A (0.65) | PDE5APDE6C | |
| SCHEMBL7163916 | 0.72 | PDE5A (0.52) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372656-B1 | PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | PFIZER LTD (GB) | 2005-06-22 | — | — | EP | disclosed |
| US-6784185-B2 | PYRAZOLO(4,3-D) PYRIMIDINONE COMPOUNDS USEFUL AS CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASES (CGMP PDES) INHIBITOR | PFIZER INC. | 2004-08-31 | — | — | US | disclosed |
| US-20020198223-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198223-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.